ArticlePLOS global public health2026
Economic impact of a large-scale scabies upsurge on healthcare facilities in Rohingya refugee camps: A retrospective costing study.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Massive scabies outbreak in Rohingya refugee camps, Cox's Bazar: Epidemiology and impact of a mass drug administration (MDA) campaign - A retrospective study.PLoS neglected tropical diseases · 2026Observational
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scabies is one of the common infectious skin conditions globally, with a significantly high burden in hot and tropical countries, and resource-poor settings. Rohingya refugee camps in Cox's Bazar are one of the most protracted refugee crises in the world, sheltering approximately 1,143,096 refugees. While most existing literature focuses on mass drug administration (MDA) interventions or community-level estimates, the economic burden of scabies on health system is rarely studied. This is a retrospective costing study, where we used financial and epidemiological data from January 2021 to December 2024. Costing was done from the provider's perspective, focused on what International Organization for Migration (IOM) spent during the period as a health service provider. A combination of standard stepdown approach and micro-costing methods were used. Financial data were collected from the IOM health programme's annual budget and consumption reports. The study population included all individuals who were clinically diagnosed with scabies and received care at 35 IOM-supported health facilities in Cox's Bazar, Bangladesh. The overall estimated financial cost for IOM's scabies outbreak response was USD 2.12 million, with an annual average of USD 531,729. The average cost per scabies management ranged between USD 5.33 and USD 6.54. Drug costs accounted for 11.92% of the overall cost over 4 years. Of the total cost of USD 253,629.43 over 4 years, 79% was attributed to permethrin topical cream, which was used to manage an estimated 85% of the total managed cases. Scenario analyses demonstrates that the existing permethrin-based treatment preference is the most expensive treatment modality, compared with ivermectin-based treatment and mixed-treatment approaches. Although the average cost of treating scabies is relatively low, overall, the treatment cost for such a large population has a significant economic impact. This study found a substantial effect of MDA on reducing the financial burden on the healthcare system.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.